{
  "relevance_rule": {
    "rule_text": "All abstracts that have Ardelyx provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Constipation",
        "Zelnorm",
        "Tegaserod",
        "IBS-C",
        "IBS",
        "Lubiprostone",
        "Linaclotide",
        "Plecanatide",
        "Tenapanor",
        "Visceral Pain",
        "Abdominal Pain",
        "Chronic Idiopathic Constipation",
        "Linzess",
        "Amitiza",
        "Trulance",
        "Prucalopride",
        "Motegrity",
        "Opioid-Induced Constipation",
        "Abdominal Distension",
        "Guanylate Cyclase C Agonists",
        "Antispasmodic",
        "Laxative",
        "EOE",
        "Neurodegenerative disorders",
        "Gastrointestinal Disorder",
        "Claudin",
        "Stomach Pain",
        "EGID",
        "Visceral Hypersensitivity",
        "Straining",
        "Functional Constipation",
        "Rome III",
        "Bloating",
        "Rome IV",
        "Nociceptive Pain",
        "NHE3",
        "SLC9A3",
        "NHE2",
        "SLC9A2",
        "SLC26A3",
        "Tight Junction",
        "Sodium Absorption",
        "Intestinal Barrier",
        "Intestinal Permeability",
        "TRPV1",
        "Enterocyte",
        "Methanogens",
        "Abdominal cramping",
        "Abdominal fullness",
        "Intestinal Lumen",
        "Sodium Hydrogen Exchange",
        "Secretagogue",
        "Patient education",
        "DGBI",
        "Abdominal symptom",
        "Abdominal symptom score",
        "Mechanisms of hepatic encephalopathy",
        "Erosive GERD",
        "Short chain fatty acids",
        "Vibrating capsule",
        "Distal intestinal obstruction syndrome (DIOS)",
        "Rome V",
        "Intercellular junction",
        "Occludin",
        "JAM-A",
        "Zonula occludens (ZO)",
        "Metagenomic / metabolomic markers",
        "Mucosal barrier dysfunction",
        "Junctional adhesion molecule",
        "Desmocollin",
        "Plakophilin",
        "Plakoglobin",
        "Phosphorylated myosin light chain (p-MLC)",
        "Myosin light chain kinase (MLCK)",
        "MLCK1",
        "Rho-associated protein kinase (ROCK)",
        "Motility Disorder",
        "ROCK1",
        "ROCK2",
        "Abdominal bloating",
        "Adherens junction",
        "Desmosome",
        "Desmoplakin",
        "Desmoglein",
        "Apical junction complex",
        "Pain",
        "Down regulated in adenoma",
        "GLP-1",
        "Dulaglutide",
        "Exenatide",
        "Semaglutide",
        "Liraglutide",
        "Lixisenatide",
        "Parkinson\u2019s Disease",
        "Cystic Fibrosis",
        "Adverse Events"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "This rule explicitly states that relevance is determined by the presence of Ardelyx provided keywords, which are listed in the client keywords."
  },
  "priority_rules": [
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored",
          "Ardelyx funded",
          "Ardelyx study",
          "Ardelyx trial"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on explicit mention of Ardelyx sponsorship, which can be identified by keyword matching."
    },
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), IBS-C, IBS (QOL, patient insights, new treatments), microbiota, and probiotics. Excludes Ardelyx sponsored abstracts.",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase II",
          "Phase 3",
          "Phase III",
          "meta-analysis",
          "meta-analyses",
          "real-world data",
          "PRO",
          "patient reported outcome",
          "registry data",
          "IBS-C",
          "IBS",
          "microbiota",
          "probiotics"
        ],
        "categories": [
          "QOL",
          "quality of life",
          "patient insights",
          "new treatments"
        ],
        "contextual_concepts": [
          "IBS studies focused on QOL, patient insights, or new treatments"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Ardelyx funded",
        "Ardelyx study",
        "Ardelyx trial"
      ],
      "reasoning": "This rule requires both keyword matching and some semantic/contextual understanding for QOL, patient insights, and new treatments in IBS studies. It is mutually exclusive from the Internal priority by excluding Ardelyx sponsored abstracts."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies. Excludes Ardelyx sponsored abstracts and all High priority concepts.",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "Phase I",
          "retrospective analysis",
          "retrospective analyses",
          "prognostic study",
          "prognostic studies",
          "trial design",
          "preclinical study",
          "preclinical studies",
          "trial outcome",
          "trial outcomes",
          "endpoint",
          "endpoints"
        ],
        "categories": [
          "general studies"
        ],
        "contextual_concepts": [
          "studies with trial outcomes and endpoints",
          "other general studies"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Ardelyx funded",
        "Ardelyx study",
        "Ardelyx trial",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "meta-analyses",
        "real-world data",
        "PRO",
        "patient reported outcome",
        "registry data",
        "IBS-C",
        "IBS",
        "microbiota",
        "probiotics",
        "QOL",
        "quality of life",
        "patient insights",
        "new treatments"
      ],
      "reasoning": "This rule requires both keyword and contextual matching for general studies and trial outcomes. It is mutually exclusive from Internal and High priority by excluding those concepts."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data. Excludes Ardelyx sponsored abstracts and all High/Medium priority concepts.",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "indication only"
        ],
        "contextual_concepts": [
          "mention of indication without any supporting data, results, or study details"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Ardelyx funded",
        "Ardelyx study",
        "Ardelyx trial",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "meta-analyses",
        "real-world data",
        "PRO",
        "patient reported outcome",
        "registry data",
        "IBS-C",
        "IBS",
        "microbiota",
        "probiotics",
        "QOL",
        "quality of life",
        "patient insights",
        "new treatments",
        "Phase 1",
        "Phase I",
        "retrospective analysis",
        "retrospective analyses",
        "prognostic study",
        "prognostic studies",
        "trial design",
        "preclinical study",
        "preclinical studies",
        "trial outcome",
        "trial outcomes",
        "endpoint",
        "endpoints",
        "general studies"
      ],
      "reasoning": "This rule requires semantic/contextual analysis to determine if only an indication is mentioned without any data, making it context-based and mutually exclusive from higher priorities."
    },
    {
      "priority": "Not Relevant",
      "rule_text": "All abstracts that do not have Ardelyx provided keywords; Abstracts that exclude IBS, IBS-C, DGBI, SIBO, and CIC but include mentions of EOE (either alone or with IBD or steroids), colonoscopy, colorectal cancer, colon cancer, renal insufficiency, dysphagia, chronic liver disease, MASLD (only when associated with DGBI), esophagogastroduodenoscopy, IBD, endoscopy, and biopsies related to esophageal issues and dysphagia.",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "EOE",
          "colonoscopy",
          "colorectal cancer",
          "colon cancer",
          "renal insufficiency",
          "dysphagia",
          "chronic liver disease",
          "MASLD",
          "esophagogastroduodenoscopy",
          "IBD",
          "endoscopy",
          "biopsy",
          "biopsies",
          "esophageal",
          "esophageal issues"
        ],
        "categories": [],
        "contextual_concepts": [
          "MASLD only when associated with DGBI",
          "biopsies related to esophageal issues and dysphagia"
        ]
      },
      "exclusions": [
        "IBS",
        "IBS-C",
        "DGBI",
        "SIBO",
        "CIC"
      ],
      "reasoning": "This rule is based on exclusion of Ardelyx keywords and specific inclusion/exclusion of other terms, which can be handled by keyword and some contextual matching."
    }
  ]
}